

SUPPLEMENTARY MATERIAL

Table S1. Characteristics of Patients by Quartiles of PTSD Symptom Check List (PCL)

<i>Patient Characteristic</i> [‡]	<i>PCL Score</i>				<i>P-value</i> [†]
	<i>17-20</i> <i>(n=58)</i>	<i>21-30</i> <i>(n=53)</i>	<i>31-46</i> <i>(n=51)</i>	<i>47-85</i> <i>(n=52)</i>	
<i>Demographics</i>					
Age, years	71 ± 8	69 ± 9	68 ± 7	68 ± 6	0.09
Male Sex	90%	89%	98%	98%	0.02
Caucasian	79%	74%	73%	79%	0.66
<i>Comorbidities and Risk Factors</i>					
History of Smoking	79%	89%	82%	75%	0.48
Hypertension	74%	79%	74%	84%	0.34
Hyperlipidemia	67%	75%	73%	78%	0.21
Diabetes Mellitus	19%	32%	34%	24%	0.52
Coronary Artery Disease	26%	30%	22%	29%	0.97
PHQ-9	2.2 ± 2.8	4.2 ± 3.0	7.6 ± 5.2	12 ± 5.8	<0.0001
Systolic Blood Pressure (mm Hg)	138 ± 21	140 ± 17	137 ± 16	145 ± 20	0.12
Diastolic Blood Pressure (mm Hg)	78 ± 10	80 ± 8	80 ± 11	82 ± 11	0.069
<i>Medications</i>					
Aspirin	57%	59%	62%	74%	0.15
Ace-inhibitor	34%	40%	28%	18%	0.047
Beta-Blocker	36%	43%	40%	27%	0.30
Statin	66%	80%	73%	81%	0.23
<i>Laboratory Studies</i>					
Total Cholesterol (mg/dl)	171 ± 43	168 ± 37	161 ± 42	167 ± 45	0.50
LDL (mg/dl)	95 ± 37	90 ± 34	87 ± 34	92 ± 35	0.52
HDL (mg/dL)	49 ± 11	50 ± 17	47 ± 11	49 ± 14	0.80
(log) Triglycerides (mg/dL)	114 ± 20	116 ± 19	109 ± 19	111 ± 19	0.67
CRP (mg/L)	2.7 ± 2.5	5.4 ± 6.2	4.7 ± 5.4	3.7 ± 3.6	0.40
eGFR (ml/min)	73 ± 22	81 ± 24	79 ± 23	79 ± 15	0.23
HgbA1C (%)	5.8 ± 0.8	6.1 ± 1.3	5.9 ± 0.6	6.0 ± 1.1	0.46

[‡] Continuous characteristics are summarized by mean (SD) and categorical by percent of quartile having the characteristic.

[†] 1 degree-of-freedom likelihood ratio tests

Table S2: Flow-mediated brachial artery vasodilation (FMD) by sample quartiles of PTSD Symptom Checklist (PCL) Score

<i>Patient Characteristic</i>	<i>PCL Score</i>				<i>P-value</i> [†]
	<i>17-20 (n=58)</i>	<i>21-30 (n=53)</i>	<i>31-46 (n=51)</i>	<i>47-85 (n=52)</i>	
Baseline Diameter (cm)	0.38 ± 0.06	0.39 ± 0.07	0.40 ± 0.06	0.41 ± 0.06	0.03
Reactive Hyperemia Diameter (cm)	0.41 ± 0.06	0.41 ± 0.07	0.42 ± 0.06	0.43 ± 0.05	--
Change from baseline with RH	0.30±0.15	0.26±0.12	0.25±0.13	0.24±0.13	--
% Change from baseline (<i>Brachial FMD</i>)	8.0 ± 4.0	7.1 ± 3.5	6.6 ± 3.7	6.1 ± 3.4	0.008
Baseline Velocity (m/s)	1.5 ± 0.7	1.7 ± 0.8	1.6 ± 0.8	1.4 ± 0.5	0.37
Reactive Hyperemia Velocity (m/s)	8.0 ± 3.0	7.6 ± 2.6	7.7 ± 2.7	8.3 ± 2.6	--
Change from baseline with RH (m/s)	6.4 ± 2.8	5.9 ± 2.8	6.1 ± 2.7	6.9 ± 2.6	0.38
Baseline Flow (mL/min)	106 ± 51	124 ± 77	121 ± 63	112 ± 49	0.62
Reactive Hyperemia Flow (mL/min)	655 ± 310	636 ± 292	672 ± 318	736 ± 261	--
Change from baseline with RH (mL/min)	548 ± 282	512 ± 262	551 ± 295	624 ± 252	0.13
Baseline Shear Stress (dynes/cm ²)	12 ± 6.0	13 ± 7.5	12 ± 6.8	10 ± 4.3	0.17
Reactive Hyperemia Shear Stress (dynes/cm ²)	55 ± 22	53 ± 20	52 ± 19	55 ± 18	--
Change from baseline with RH (dynes/cm ²)	43 ± 20	40 ± 21	40 ± 17	45 ± 19	0.70

[†] To avoid inflating the type-1 error rate (false-positive claims), statistical tests (3 degree-of-freedom likelihood ratio tests) examined one measure each of variation at start and at end of vasodilation challenge.